He et al. found that Tau-6 levels in the hippocampus of BBR-treated AD mice (p-S199, p-S202, p-T205, p-T231, p-S396 and p-S404) significantly decreased, strongly reducing tau hyperphosphorylation in the hippocampus of APP/PS1 mice [106]. This evidence concerns the gene MAPT and Alzheimer disease.